Surgical robotics firm Stereotaxis Q4 revenue jumps

Stereotaxis

09/03/2026 20:12

Overview

Surgical robotics firm's Q4 revenue grew 36% yr/yr

Company achieved regulatory approvals for GenesisX and MAGiC products

Company anticipates double-digit revenue growth for 2026

Outlook

Stereotaxis anticipates double-digit revenue growth for full year 2026

Company expects annual revenue to surpass $40 mln

Stereotaxis aims for reduced cash use and positive cash flow in 2026

Result Drivers

PRODUCT LAUNCHES - Revenue growth driven by GenesisX robots and MAGiC Sweep contributions in US and Europe

MANUFACTURING CHALLENGES - Commercial contribution from new products limited due to manufacturing ramp-up issues

Company press release: ID:nGNX49bNzw

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$8.64 mln
Q4 EPS
-$0.06
Q4 Net Income
-$5.53 mln
Q4 Operating Expenses
$9.98 mln
Q4 Operating Income
-$5.65 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Stereotaxis Inc is $4.00, about 93.7% above its March 6 closing price of $2.07

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)